GIULIO DRAETTA to Cell Line, Tumor
This is a "connection" page, showing publications GIULIO DRAETTA has written about Cell Line, Tumor.
Connection Strength
0.289
-
In?Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. Cell Rep. 2016 06 28; 16(1):133-147.
Score: 0.046
-
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor. J Med Chem. 2021 10 28; 64(20):15141-15169.
Score: 0.017
-
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nat Commun. 2021 07 30; 12(1):4626.
Score: 0.016
-
miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. EMBO Mol Med. 2021 07 07; 13(7):e12872.
Score: 0.016
-
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. J Med Chem. 2020 11 12; 63(21):12957-12977.
Score: 0.016
-
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. Cancer Res. 2020 11 01; 80(21):4840-4853.
Score: 0.015
-
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. Cancer Res. 2019 Nov 01; 79(21):5612-5625.
Score: 0.014
-
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019 05 08; 11(491).
Score: 0.014
-
p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9.
Score: 0.014
-
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation. Cell Rep. 2019 01 08; 26(2):469-482.e5.
Score: 0.014
-
An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018 07; 24(7):1036-1046.
Score: 0.013
-
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Res. 2017 12 01; 77(23):6651-6666.
Score: 0.013
-
In Vivo Genetic Screens of Patient-Derived Tumors Revealed Unexpected Frailty of the Transformed Phenotype. Cancer Discov. 2016 06; 6(6):650-63.
Score: 0.011
-
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. Cancer Res. 2015 Sep 15; 75(18):3865-3878.
Score: 0.011
-
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. Antioxid Redox Signal. 2015 Jul 01; 23(1):15-29.
Score: 0.011
-
Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Cell. 2014 Jul 03; 158(1):185-197.
Score: 0.010
-
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol. 2009 Nov; 158(5):1183-95.
Score: 0.007
-
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 2009 Apr 01; 69(7):3060-8.
Score: 0.007
-
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med. 2007 Aug 06; 204(8):1813-24.
Score: 0.006
-
Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol. 2007 Jul; 27(13):4784-95.
Score: 0.006
-
Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol. 2007 Feb; 14(2):209-19.
Score: 0.006
-
Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol Cell Biol. 2005 Apr; 25(8):3338-47.
Score: 0.005